Spero Therapeutics (NASDAQ:SPRO) Earns “Hold” Rating from TD Cowen

TD Cowen reissued their hold rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a report released on Monday,Benzinga reports.

SPRO has been the topic of a number of other research reports. HC Wainwright lowered their price objective on Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research note on Friday.

Spero Therapeutics Stock Down 3.4 %

Shares of NASDAQ:SPRO opened at $1.14 on Monday. Spero Therapeutics has a fifty-two week low of $1.01 and a fifty-two week high of $1.89. The firm’s 50-day simple moving average is $1.29 and its 200-day simple moving average is $1.36. The company has a market cap of $61.55 million, a price-to-earnings ratio of 16.29 and a beta of 0.63.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in shares of Spero Therapeutics during the 1st quarter valued at approximately $31,000. Acadian Asset Management LLC increased its stake in Spero Therapeutics by 121.8% in the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after purchasing an additional 418,742 shares in the last quarter. Murchinson Ltd. raised its holdings in Spero Therapeutics by 1.3% during the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after purchasing an additional 11,210 shares during the last quarter. Renaissance Technologies LLC boosted its position in Spero Therapeutics by 14.2% during the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after purchasing an additional 121,492 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Spero Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after purchasing an additional 9,675 shares during the last quarter. 25.60% of the stock is currently owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.